Toll Free: 1-888-928-9744
Published: Jul, 2015 | Pages:
38 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Adamis Pharmaceuticals Corporation - Product Pipeline Review - 2015 Summary Global Markets Direct's, 'Adamis Pharmaceuticals Corporation - Product Pipeline Review - 2015', provides an overview of the Adamis Pharmaceuticals Corporation's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Adamis Pharmaceuticals Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Adamis Pharmaceuticals Corporation including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Adamis Pharmaceuticals Corporation's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Adamis Pharmaceuticals Corporation's pipeline products Reasons to buy - Evaluate Adamis Pharmaceuticals Corporation's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Adamis Pharmaceuticals Corporation in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Adamis Pharmaceuticals Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Adamis Pharmaceuticals Corporation and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Adamis Pharmaceuticals Corporation - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Explore the dormant and discontinued projects of Adamis Pharmaceuticals Corporation and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Adamis Pharmaceuticals Corporation Snapshot 5 Adamis Pharmaceuticals Corporation Overview 5 Key Information 5 Key Facts 5 Adamis Pharmaceuticals Corporation - Research and Development Overview 6 Key Therapeutic Areas 6 Adamis Pharmaceuticals Corporation - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Combination Treatment Modalities 11 Adamis Pharmaceuticals Corporation - Pipeline Products Glance 12 Adamis Pharmaceuticals Corporation - Late Stage Pipeline Products 12 Filing rejected/Withdrawn Products/Combination Treatment Modalities 12 Adamis Pharmaceuticals Corporation - Clinical Stage Pipeline Products 13 Phase II Products/Combination Treatment Modalities 13 Phase I Products/Combination Treatment Modalities 14 Adamis Pharmaceuticals Corporation - Early Stage Pipeline Products 15 Preclinical Products/Combination Treatment Modalities 15 Adamis Pharmaceuticals Corporation - Drug Profiles 16 epinephrine 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 (fluticasone propionate + salmeterol xinafoate) 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 APC-3000 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 beclomethasone dipropionate 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 APC-100 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 TeloB-VAX 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 APC-200 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 APC-300 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 C-31G 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Adamis Pharmaceuticals Corporation - Pipeline Analysis 27 Adamis Pharmaceuticals Corporation - Pipeline Products by Target 27 Adamis Pharmaceuticals Corporation - Pipeline Products by Route of Administration 28 Adamis Pharmaceuticals Corporation - Pipeline Products by Molecule Type 29 Adamis Pharmaceuticals Corporation - Pipeline Products by Mechanism of Action 30 Adamis Pharmaceuticals Corporation - Recent Pipeline Updates 31 Adamis Pharmaceuticals Corporation - Dormant Projects 34 Adamis Pharmaceuticals Corporation - Discontinued Pipeline Products 35 Discontinued Pipeline Product Profiles 35 C-31G 35 Adamis Pharmaceuticals Corporation - Locations And Subsidiaries 36 Head Office 36 Other Locations & Subsidiaries 36 Appendix 37 Methodology 37 Coverage 37 Secondary Research 37 Primary Research 37 Expert Panel Validation 37 Contact Us 37 Disclaimer 38
List of Tables
Adamis Pharmaceuticals Corporation, Key Information 5 Adamis Pharmaceuticals Corporation, Key Facts 5 Adamis Pharmaceuticals Corporation - Pipeline by Indication, 2015 8 Adamis Pharmaceuticals Corporation - Pipeline by Stage of Development, 2015 9 Adamis Pharmaceuticals Corporation - Monotherapy Products in Pipeline, 2015 10 Adamis Pharmaceuticals Corporation - Combination Treatment Modalities in Pipeline, 2015 11 Adamis Pharmaceuticals Corporation - Filing rejected/Withdrawn, 2015 12 Adamis Pharmaceuticals Corporation - Phase II, 2015 13 Adamis Pharmaceuticals Corporation - Phase I, 2015 14 Adamis Pharmaceuticals Corporation - Preclinical, 2015 15 Adamis Pharmaceuticals Corporation - Pipeline by Target, 2015 27 Adamis Pharmaceuticals Corporation - Pipeline by Route of Administration, 2015 28 Adamis Pharmaceuticals Corporation - Pipeline by Molecule Type, 2015 29 Adamis Pharmaceuticals Corporation - Pipeline Products by Mechanism of Action, 2015 30 Adamis Pharmaceuticals Corporation - Recent Pipeline Updates, 2015 31 Adamis Pharmaceuticals Corporation - Dormant Developmental Projects,2015 34 Adamis Pharmaceuticals Corporation - Discontinued Pipeline Products, 2015 35 Adamis Pharmaceuticals Corporation, Subsidiaries 36
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.